DRESS Syndrome Clinical Guidelines

Introduction to DRESS Syndrome

• DRESS syndrome is a rare, potentially life-threatening drug-induced hypersensitivity reaction characterized by a morbilliform rash involving >30% of body surface area, fever >38°C, eosinophilia, lymphadenopathy, and multi-organ involvement that typically occurs 2-6 weeks after exposure to the offending medication 1, 2

Key Clinical Features

• The reaction occurs after a characteristic latent period of 2-6 weeks following drug exposure, distinguishing it from other immediate drug reactions 1, 2
• The most common skin finding is a morbilliform (maculopapular) confluent rash that typically involves more than 30% of body surface area 1, 2
• The rash is accompanied by fever and constitutional symptoms including rigors, myalgias, and arthralgias 3
• Hepatitis is the most common organ manifestation, with ALT >2 times the upper limit of normal 2
• Kidney involvement presents as nephritis with creatinine >1.5 times baseline 2
• Cardiac involvement can include myocarditis and pericarditis 1
• Eosinophilia is a hallmark feature, defined as >700/μL or >10% of white blood cells 2
• Lymphadenopathy is commonly present 1, 2

Pathophysiology and Genetic Predispositions

• The syndrome involves reactivation of herpes family viruses (particularly EBV and HHV-6) and activation of lymphocytes, leading to T-cell immune-directed toxicity 1
• Genetic predispositions through the major histocompatibility complex (MHC) play a significant role, with specific HLA associations linked to particular drug reactions (e.g., HLA-B*58:01 with allopurinol-induced DRESS) 1, 2

Diagnostic Approach

• The diagnosis is clinical, based on the RegiSCAR scoring system that classifies cases as "no," "possible," "probable," or "definite" based on clinical and laboratory findings 2
• Complete blood count with differential to assess for eosinophilia 2
• Comprehensive metabolic panel evaluating liver function (ALT, AST, alkaline phosphatase, bilirubin) and kidney function (BUN, creatinine) 2
• Urinalysis to evaluate for nephritis 2, 3
• Skin biopsy if diagnosis is uncertain 3

Management Principles

• Immediate discontinuation of the suspected causative drug is the first and most crucial step, followed by prompt dermatology consultation 1, 3
• Systemic corticosteroids are first-line therapy (IV methylprednisolone 1-2 mg/kg/day), with weaning over at least 4 weeks required due to T-cell immune-directed toxicity 1, 3
• Severe cases require admission to burn unit or ICU with dermatology and wound care services consultation 3
• Unlike in Stevens-Johnson syndrome, corticosteroids are not contraindicated in DRESS syndrome 3
• For steroid-unresponsive cases, consider intravenous immunoglobulin (IVIG) at 1-2 g/kg total dosage or cyclosporine 3
• Supportive care includes fluid and electrolyte management, infection prevention, topical corticosteroids, and oral antihistamines 1, 3

DRESS Syndrome Diagnosis and Management

Diagnostic Considerations

• The American Academy of Allergy, Asthma, and Immunology recommends patch testing or delayed intradermal testing to identify the culprit drug, but only after at least 6 months after the acute reaction and at least 1 month after discontinuation of systemic corticosteroids 4, 5
• The European Academy of Allergology and Clinical Immunology suggests that delayed intradermal testing with reading at 24 hours may be useful for DRESS diagnosis 5

Management Principles

• The American College of Dermatology advises against drug challenge with the suspected drug, except in extreme circumstances where benefit outweighs risk 5
• The National Institute of Allergy and Infectious Diseases recommends a minimum 4-week taper of steroids to prevent relapse 4, 5

DRESS Syndrome Diagnosis and Management

Diagnostic Approach

• The latency period of DRESS syndrome, which distinguishes it from immediate drug reactions, is critical for identifying the culprit drug, and typically occurs 2-6 weeks after drug exposure, according to the American Academy of Allergy, Asthma, and Immunology 6

Critical Pitfalls to Avoid

• The American Academy of Allergy, Asthma, and Immunology recommends that patch testing or delayed intradermal testing should not be performed until at least 6 months after complete resolution and at least 4 weeks after discontinuing systemic steroids (>10 mg prednisone equivalent), with evidence quality being very low for these modalities 6, 7
• Drug challenge with the suspected culprit is contraindicated, except in extreme circumstances, due to the severe T-cell-mediated delayed reaction with long-lasting memory responses, as stated by the American Academy of Allergy, Asthma, and Immunology 8

Adjunctive Diagnostic Testing

• The American Academy of Allergy, Asthma, and Immunology suggests that delayed intradermal testing and/or patch testing may support drug causality, but only after the appropriate waiting period, with testing parameters including delayed intradermal: 0.02-0.05 mL volume, read at 24 hours for induration, and patch testing: 10-30% trade product or 1-10% pure substance, remove at 48 hours with readings at 24-72 hours, 96 hours, and 7 days 6, 7

DRESS Syndrome: Clinical Features and Causative Medications

Causative Medications

• The British Journal of Pharmacology reports that antibiotics, such as vancomycin, sulfonamides, and beta-lactams, account for 74% of DRESS syndrome cases, while anticonvulsants, including phenytoin, carbamazepine, and phenobarbital, account for 21% of cases 9
• Antiretrovirals, particularly nevirapine and abacavir, are also implicated in DRESS syndrome, with incidence rates of 17-32% and 2.3-9%, respectively 9

Differential Diagnosis

• DRESS syndrome can be distinguished from Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) by the presence of eosinophilia, longer latency period, and prominent organ involvement, as noted in the British Journal of Pharmacology 9

DRESS Syndrome Diagnostic Criteria

Clinical Presentation

• The presence of fever, skin eruption, hematologic abnormalities, and systemic involvement are required for the diagnosis of DRESS syndrome, with a sensitivity of 77.1% compared to RegiSCAR's 60.4% for definite cases, according to the European Society of Clinical Microbiology and Infectious Diseases 10

Laboratory Abnormalities

• Urinalysis is necessary to assess for nephritis, and blood cultures should be performed if the patient is febrile to rule out infectious mimics, as recommended by the Infectious Diseases Society of America 10
• Skin biopsy may be necessary if the diagnosis is uncertain, showing perivascular lymphocytic infiltration with dermal edema, according to the American Academy of Dermatology 10

Prognostic Indicators

• Elevated serum creatinine and ferritin levels at presentation predict fatal outcomes, while higher lymphocyte counts indicate the need for systemic corticosteroids, as stated by the European Respiratory Society 10

Managing Heart Failure in DRESS Syndrome

Heart Failure Assessment and Management

• The American Heart Association recommends assessing NYHA functional class and left ventricular ejection fraction to guide heart failure management, as cardiac involvement in DRESS occurs in 4-21% of cases 11, 12
• The American College of Cardiology suggests using diuretics and salt restriction for fluid retention, with loop diuretics (furosemide 20-40 mg once or twice daily, titrated to effect) 12
• The American College of Cardiology recommends using ACE inhibitors for heart failure with reduced ejection fraction, unless contraindicated, and beta-blockers (bisoprolol, carvedilol, or sustained-release metoprolol succinate) for stable patients with reduced LVEF 12

Contraindications and Cautions

• The British Association of Dermatologists advises avoiding TNF antagonist therapy entirely if severe (NYHA class III-IV) heart failure is present, as trials showed excess mortality with infliximab 11, 13, 14
• The American College of Cardiology recommends withdrawing calcium channel blockers with negative inotropic effects in patients with ejection fraction <40% 12
• The American College of Cardiology suggests discontinuing NSAIDs as they adversely affect heart failure outcomes and may have been the causative agent for DRESS 12

Corticosteroid Therapy

• The Journal for ImmunoTherapy of Cancer recommends planning for a minimum 4-week taper to prevent relapse, as DRESS involves T-cell immune-directed toxicity with long-lasting memory responses, and starting proton pump inhibitor for gastrointestinal prophylaxis during corticosteroid therapy 15

Refractory Cases and Long-Term Considerations

• The Journal of Allergy and Clinical Immunology advises against premature steroid taper (minimum 4 weeks required), as relapse occurs in 12% of cases, and against rechallenging with the suspected drug, as DRESS involves severe T-cell-mediated delayed reactions with long-lasting memory 16

Evidence‑Based Clinical Features and Diagnostic Strategies for DRESS Syndrome

Cutaneous Manifestations

• In patients with DRESS, a morbilliform (maculopapular) confluent rash covering more than 30 % of body surface area is the most frequent skin finding. 17
• The same rash characteristic is corroborated by an additional study, reinforcing its prevalence in DRESS cohorts. 18

Causative Drugs

Antiretroviral Agents

• Nevirapine precipitates DRESS in approximately 17 %–32 % of exposed individuals, frequently accompanied by fever and hepatitis. 17
• Reactions to nevirapine typically emerge within three months of therapy initiation and tend to be more severe after drug rechallenge. 18
• The HLA‑B*3505 allele has been linked to nevirapine‑induced DRESS in Thai populations, suggesting a genetic susceptibility. 18

Non‑Steroidal Anti‑Inflammatory Drugs (NSAIDs)

• NSAIDs are a common cause of delayed drug‑hypersensitivity reactions, yet they account for less than 5 % of all DRESS cases. 19
• Oxicam derivatives (e.g., meloxicam, piroxicam) and acetic‑acid NSAIDs (e.g., diclofenac) show a higher association with severe cutaneous adverse drug reactions within the DRESS spectrum. 19

Diagnostic Testing

Delayed Intradermal Testing (dIDT) and Patch Testing

• dIDT and patch testing can aid in identifying the culprit drug, but they should only be performed ≥ 6 months after complete clinical resolution and ≥ 4 weeks after discontinuation of systemic steroids (≥ 10 mg prednisone‑equivalent). [20][21]
• dIDT protocol: inject 0.02–0.05 mL of the suspect drug intradermally; read induration at 24 hours.
• Patch‑test protocol: apply 10–30 % of the commercial formulation or 1–10 % of the pure substance; remove after 48 hours and read at 24–72 hours, 96 hours, and 7 days. Both protocols are supported by recent allergology guidelines. [20][21]

Use of Loratadine and Antihistamines in Suspected DRESS

Antihistamine Therapy for Pruritus in DRESS

Timing and Sensitivity of Patch Testing in DRESS

Cutaneous Histopathology Findings in DRESS Syndrome

Histopathologic Characteristics

• Skin biopsy in DRESS syndrome typically reveals a dermal infiltrate predominated by CD4⁺ lymphocytes, accompanied by eosinophils and papillary edema, which helps confirm the diagnosis of drug‑induced hypersensitivity reaction. 24

Management of Painful Oral Ulcers in DRESS Syndrome

Immediate Systemic Management

• Discontinue the offending β‑lactam antibiotic promptly and start systemic corticosteroid therapy with intravenous methylprednisolone at 1–2 mg/kg/day; add high‑potency topical corticosteroids (dexamethasone 0.1 mg/mL mouth rinse or clobetasol 0.05 % gel) together with viscous lidocaine 2 % and an oral antihistamine for pain and pruritus control. 25

Topical Corticosteroid Management for Oral Ulcers

• Use dexamethasone 0.1 mg/mL mouth rinse when ulcerations involve multiple oral sites or are difficult to reach.
• Apply clobetasol 0.05 % gel or ointment for limited, easily accessible ulcers.
• Increase the frequency of a bland, non‑alcoholic sodium‑bicarbonate mouthwash to up to hourly as needed for additional soothing. 25, 26

Pain Management Algorithm

Mild to Moderate Pain

• Begin with viscous lidocaine 2 % mouthwash for immediate topical analgesia.
• If the mouthwash is painful, apply a protective coating agent before using other rinses. 25, 26

Moderate Pain Escalation

• Add a topical non‑steroidal anti‑inflammatory paste (amlexanox 5 %) for moderate‑level discomfort.
• If a topical NSAID is not tolerated, substitute acetaminophen (paracetamol) for maintenance analgesia.
• For short‑term breakthrough pain before meals, combine the above with an immediate‑release oral opioid or a fast‑acting fentanyl nasal spray (≈50 µg). 25, 26

Severe or Persistent Pain

• Follow the WHO analgesic ladder, progressing to stronger opioids as required.
• Consider alternative delivery routes (transdermal patches or intranasal formulations) because oral ulceration may limit oral drug administration. 25, 26

Advanced Interventions for Refractory Ulcers

• Perform intralesional triamcinolone injections (weekly, total ≈28 mg) together with continued topical clobetasol 0.05 % gel/ointment for ulcers that do not resolve with first‑line therapy.
• In cases of highly symptomatic or recurrent ulcers, the systemic corticosteroids already prescribed for DRESS are generally sufficient to control ulcer severity. 25, 26

Diagnosis and Red‑Flag Management of DRESS Syndrome

Distinguishing Clinical Features

Critical Red‑Flag Indicators of Possible Progression to SJS/TEN

Immediate Evaluation Imperative